Monopar Therapeutics (NASDAQ:MNPR) Upgraded to “Strong-Buy” at Jones Trading

Monopar Therapeutics (NASDAQ:MNPR) was upgraded by stock analysts at Jones Trading from a “hold” rating to a “strong-buy” rating in a research report issued to clients and investors on Friday,Zacks.com reports.

A number of other equities research analysts have also recently weighed in on MNPR. Raymond James Financial set a $142.00 price objective on Monopar Therapeutics and gave the company a “strong-buy” rating in a research note on Monday. Oppenheimer set a $115.00 price target on Monopar Therapeutics and gave the stock an “outperform” rating in a research note on Thursday, October 2nd. HC Wainwright set a $105.00 price target on Monopar Therapeutics and gave the stock a “buy” rating in a research note on Monday, September 29th. BTIG Research upped their price target on Monopar Therapeutics from $87.00 to $104.00 and gave the stock a “buy” rating in a research note on Thursday, September 25th. Finally, Piper Sandler set a $95.00 price target on Monopar Therapeutics and gave the stock an “overweight” rating in a research note on Thursday, September 25th. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $103.25.

Monopar Therapeutics Trading Down 13.0%

Shares of NASDAQ MNPR opened at $87.82 on Friday. Monopar Therapeutics has a twelve month low of $4.50 and a twelve month high of $105.00. The stock has a 50 day moving average of $54.12 and a two-hundred day moving average of $43.28. The stock has a market cap of $541.85 million, a P/E ratio of -26.37 and a beta of 1.42.

Monopar Therapeutics (NASDAQ:MNPR) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.35) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.12. As a group, research analysts predict that Monopar Therapeutics will post -1.65 earnings per share for the current year.

Insiders Place Their Bets

In other Monopar Therapeutics news, Director Christopher M. Starr sold 16,800 shares of the stock in a transaction on Monday, July 14th. The stock was sold at an average price of $40.00, for a total value of $672,000.00. Following the completion of the transaction, the director owned 5,173 shares in the company, valued at approximately $206,920. This represents a 76.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Kim R. Tsuchimoto sold 8,904 shares of the stock in a transaction on Monday, July 14th. The stock was sold at an average price of $40.00, for a total value of $356,160.00. Following the completion of the transaction, the director owned 11,486 shares of the company’s stock, valued at $459,440. The trade was a 43.67% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 592,733 shares of company stock worth $36,700,227. 20.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of Monopar Therapeutics in the second quarter valued at $80,000. Affinity Asset Advisors LLC increased its position in shares of Monopar Therapeutics by 8.9% in the second quarter. Affinity Asset Advisors LLC now owns 67,500 shares of the company’s stock valued at $2,415,000 after buying an additional 5,500 shares in the last quarter. New York State Common Retirement Fund purchased a new position in shares of Monopar Therapeutics in the second quarter valued at $104,000. Rhumbline Advisers purchased a new position in shares of Monopar Therapeutics in the second quarter valued at $209,000. Finally, JPMorgan Chase & Co. increased its position in shares of Monopar Therapeutics by 1,821.0% in the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock valued at $69,000 after buying an additional 1,821 shares in the last quarter. Hedge funds and other institutional investors own 1.83% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.